News

22 Jul

Posted at 09:59h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Given the good track record of the stock market as an alternative source of financing, the biotechnology company Laminar Pharma is taking its first steps to attract private investors and institutions, by joining...

29 May

Posted at 16:03h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Following the positive conclusion of a PI/IIa trial in Europe with 2OHOA in adult patients with advanced solid tumours, including malignant glioma, this paediatric trial will investigate the safety profile and preliminary anticancer...

22 Jan

Posted at 16:02h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Laminar Pharma and integrated by 12 leading clinical research institutions, Universities and SMEs...

05 Jun

Posted at 06:52h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]54 patients with advanced solid tumours have participated in the Phase I/IIa clinical study with 2OHOA, half of them with malignant glioma. Primary objective has been achieved, with the definition or the MTD,...

12 Dec

Posted at 12:38h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca (Spain), December 12th 2016 –   The postdoctoral researcher Catalina Ana Rosselló Castillo has been awarded a Felip Bauçà fellowship at the CAIB (Comunitat Autònoma de les Illes Balears) Postdoctoral call from the...

01 Aug

Posted at 12:43h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma announces the closure of patient recruitment in its first clinical study with 2OHOA (MIN-001-1203), a Phase I/IIa open label, non-randomized, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy study of 2OHOA in adult...

23 Nov

Posted at 12:53h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca (Spain), November 23rd 2015 –   Laminar Pharma announced today that in the Dose Escalation TC held this morning with all the Clinical Investigators and the Medical Monitor of the MIN-001-1203 study...

29 May

Posted at 13:27h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, May 30th 2015 –   Updated results of the ongoing Phase I/IIA clinical trial with 2OHOA in patients with advanced solid tumours, including malignant glioma (MIN-001-1203), were presented today in a poster discussion session at...

07 Apr

Posted at 13:31h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, April 07, 2015 –   Laminar Pharma announced today that a key patent for the company, owned by the University of the Balearic Islands (UIB) and licensed in exclusive to Laminar Pharma, has...

04 Nov

Posted at 13:33h in News

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, November 04th, 2014 –   Laminar Pharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with 2OHOA...